Interference Analysis of Monoclonal Antibody Cluster of Differentiation 38 on ABO Blood Group Identification and Cross-Matching

We attempt to analyze and adopt the interference of monoclonal antibody cluster differentiation 38 on ABO blood group identification cross-matching. Search PubMed, Medline, Web Science, China National Knowledge Infrastructure, Wanfang other domestic foreign databases, screening patients requiring transfusion after receiving anti-cluster antibody, retrospective analysis anti-human globulin cassette method for cross-matching serum from treated with antibody. According search results, a total 185 who received as monotherapy or combination therapy required were retrieved. Among them, 98 cases multiple myeloma, 22 chronic lymphocytic leukemia 16 relapsed acute myeloid leukemia, was 136 cases. But among 124 daratumab treatment, 49 (39.5 %) 236 transfusions during treatment. these, 47 (37.9 147 red cell infusions, 17 (13.7 89 platelet transfusions. systemic lupus erythematosus patients, there only one case transfusion-related reactions (rather than cell) no adverse reactions. In investigation bone marrow-related diseases, we found that 5 developed indirect antiglobulin test weakly positive, all did not see any discrepancies in type identification. Antibody identified panagglutination occurred 1 patient myeloma. myeloma possessed low expression surface erythrocytes its level does differ between individuals. After injections, macrophages increased, i.e. antigen molecules patient’s own erythrocyte falls off. Cluster substantially made ABO, rhesus extended matching. cross-matching, caused at test, showing agglutination intensity 1+ weaker reactivity. Hematological diseases such anticluster reactivity;